1. Scrip
  2. >>New Products

Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos

 
• By Joseph Haas

Eighty percent of patients who’ve received Genvoya so far are switched over from older Gilead regimens, while 10% have switched from non-Gilead drugs. In terms of cumulative prescriptions, the Genvoya launch is outpacing the launch of predecessor drug Stribild to date.

The future of Gilead Sciences Inc.’s HIV business depends on switching patients over to its newer HIV single-tablet regimens where the older Viread is replaced with the prodrug tenofovir alafenamide (TAF), and not only did it report strong starts in the third quarter, it has new evidence in hand that should help it convert patients from the old to the new.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch: 13 Approvals And 13 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

 
• By Anju Ghangurde

In the final part of this interview with Scrip, Menarini’s Asia-Pacific CEO talks about the Italian group’s digital capabilities, including the impact made during a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The company is also revving up its business development and alliance engine, with around 14 candidates under evaluation at different stages at the regional level.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain.